Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses two studies in BRAF-mutated colorectal cancer (CRC).
The studies were both presented at the 2014 ASCO Annual Meeting. The first was an open-label phase I/II study of trametinib, dabrafenib, and panitumumab in combination for patients with BRAF V600E
mutated CRC. The second was a phase I study exploring the novel agent encorafenib (LGX818) combined with cetuximab with or without BYL719 in patients with advanced BRAF
Bendell says both of these studies showed a response rate of about 35-40%. Usually, patients with BRAF
-mutant CRC treated with single-agent chemotherapy only have a response rate of less than 10%. This study showed that an in-depth understanding of molecularly targeted agents and pathways really makes sense, Bendell says.
<<< View more from the 2014 ASCO Annual Meeting